Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
K John PasiKathelijn FischerMargaret V RagniRoshni Daniel KulkarniMargareth C OzeloJohnny N MahlanguAmy D ShapiroStephanie P'NgHervé ChambostBeatrice NolanCarolyn BennettTadashi MatsushitaBent WindingJoachim FruebisHuixing YuanDan RudinJohannes OldenburgPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)
B-YOND results confirm the long-term (up to 5 years, with cumulative duration up to 6.5 years) well-characterized safety and efficacy of rFIXFc treatment for haemophilia B.
Keyphrases